Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ximelagatran: a clinical perspective.

C J Boos1, A Hinton, G Y H Lip

  • 1Department of Cardiology, Southampton General Hospital, Tremona Rd, Southampton, UK.

European Journal of Internal Medicine
|August 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intercellular Communication via Mitotic Nanotubes is Influenced by Connexin-43 Trafficking and Actin Remodeling.

bioRxiv : the preprint server for biology·2026
Same author

Long-term impact of combat-related traumatic injury on heart rate variability: findings from the ADVANCE study.

BMJ military health·2025
Same author

Biopsychosocial factors and low back pain in military personnel with lower limb loss: the ADVANCE study.

BMJ military health·2025
Same author

Social determinants of health and clinical outcomes among patients with atrial fibrillation: evidence from a global federated health research network.

QJM : monthly journal of the Association of Physicians·2023
Same author

Pharmacokinetics and pharmacodynamics of direct oral anticoagulants.

Expert opinion on drug metabolism & toxicology·2023
Same author

Cerebrovascular risk factors and their time-dependent effects on stroke survival in the EMMA cohort study.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2023
Same journal

Artificial intelligence in diagnostics and medical decision making.

European journal of internal medicine·2026
Same journal

Diagnosis, treatment and outcomes of euvolemic hyponatremia among geriatric hospitalised patients.

European journal of internal medicine·2026
Same journal

Sex-based differences and clinical outcomes in older adults with Candida bloodstream infection: a post-hoc secondary analysis of a multicentre study.

European journal of internal medicine·2026
Same journal

Have mediators and at-risk time shaped the Lipoprotein(a)-dementia null? Author's reply.

European journal of internal medicine·2026
Same journal

Using latent class analysis for identifying clinical phenotypes associated with prognosis in patients with atrial high-rate episodes.

European journal of internal medicine·2026
Same journal

Severe hyperkalaemia during liposomal amphotericin B treatment, independent of nephrotoxicity.

European journal of internal medicine·2026
See all related articles

Ximelagatran, a new oral anticoagulant and direct thrombin inhibitor, shows promise in preventing blood clots across various conditions. While generally safe, it requires liver function monitoring due to potential dysfunction in some patients.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Ximelagatran represents a new class of oral anticoagulants, direct thrombin inhibitors.
  • It has undergone extensive evaluation in large-scale clinical trials for various thrombotic conditions.

Purpose of the Study:

  • To review clinical trials of ximelagatran.
  • To assess its efficacy, safety, and potential impact on thrombosis management.

Main Methods:

  • Review of numerous large-scale, randomized controlled clinical trials.
  • Inclusion of data from studies on thromboprophylaxis, deep vein thrombosis treatment, stroke prevention in atrial fibrillation, and post-myocardial infarction secondary prevention.

Main Results:

Related Experiment Videos

  • Ximelagatran demonstrated efficacy in multiple indications, including venous thromboembolism prophylaxis and stroke prevention.
  • A notable side effect is liver dysfunction in approximately 6% of patients, necessitating monitoring.
  • It offers advantages over vitamin K antagonists, including a wide therapeutic interval and no need for routine anticoagulant monitoring.

    • Conclusions:

    • Ximelagatran is the first new oral anticoagulant in over 60 years.
    • It is poised to significantly influence the management of thrombosis-related disorders.
    • Careful monitoring for liver function is recommended during initial treatment phases.